 That's just a beginning effort that points to a very wide and diverse range of relationships across the government and business worlds of biotech and pharma, where we have relationships with China that are worthy of reconsideration. Well, regrettably, we've run out of time, but I do encourage you to pick up 64-page report, more than 220 footnotes, very thoroughly researched. And please join me in thanking our panelists for this great discussion. Thank you.